TRACON Pharmaceuticals, Inc.

TCON

US89237H3084

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-07 EDT			5-day change	1st Jan Change
1.14 ^USD	-3.39%		-10.94%	-67.45%

05-14	TRACON Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-14	Transcript : TRACON Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024

TRACON Pharmaceuticals Appoints Shahe Garabedian as Senior Vice President of Quality Assurance

April 14, 2020 at 09:15 am

TRACON Pharmaceuticals announced the appointment of Shahe Garabedian as Senior Vice President of Quality Assurance and the issuance of an inducement award. Most recently, he was Vice President of Quality at Arena Pharmaceuticals.

Latest news about TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Transcript : TRACON Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024	05-14
Earnings Flash (TCON) TRACON PHARMACEUTICALS Posts Q1 Revenue $100,000	05-14	MT
Tracon Pharmaceuticals, Inc. Appoints David Lazar as Chief Business Development Officer	05-13	CI
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned	04-03	CI
HC Wainwright Adjusts Price Target on TRACON Pharmaceuticals to $6 From $7, Keeps Buy Rating	03-06	MT
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-05	CI
Transcript : TRACON Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 05, 2024	03-05
Earnings Flash (TCON) TRACON PHARMACEUTICALS Reports Q4 Revenue $3M, vs. Street Est of $1.5M	03-05	MT
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-05	CI
TRACON Pharmaceuticals, Inc. Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial	12-20	CI
Tracon Licenses Product Development Platform for $3 Million Upfront Payment; Shares Jump	11-20	MT
TRACON Pharmaceuticals, Inc. Announces License of Product Development Platform for $3.0 Million Upfront Payment	11-20	CI
Wall Street Set to Open Slightly Higher as Investors Parse Powell Remarks	11-10	MT
Exchange-Traded Funds, Equity Futures Rise After Fed Chief's Comments	11-10	MT
Investors Parse Powell Remarks as US Futures Advance Slightly in Friday Trading	11-10	MT
Top Premarket Gainers	11-10	MT
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Transcript : TRACON Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 09, 2023	11-09
TRACON Pharmaceuticals, Inc. Announces Resignation of Bonne Adams as Chief Operating Officer, Effective October 15, 2023	23-10-06	CI
TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned	23-09-18	CI
North American Morning Briefing : Stock Futures -2-	23-08-22	DJ
JonesTrading Downgrades TRACON Pharmaceuticals to Hold From Buy	23-08-21	MT
Baird Trims Price Target on TRACON Pharmaceuticals to $3 From $7, Maintains Outperform Rating	23-08-15	MT
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI

Chart TRACON Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize products in the United States. The Companyâs clinical-stage oncology product candidate is TRC102, which is a small molecule that has been studied in Phase 1 and Phase 2 trials for the treatment of mesothelioma, lung cancer, glioblastoma and solid tumors and YH001, which is a monospecific investigational cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody. TRC102 is a small molecule in clinical development to reverse resistance to specific chemotherapeutics by inhibiting DNA base excision repair (BER). Its clinical-stage product candidate, Envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma.

Sector

Pharmaceuticals

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.18 USD

Average target price

30.5 USD

Spread / Average Target

+2,484.75%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
TRACON PHARMACEUTICALS, INC.	-67.45%	3.16M
CSL LIMITED	+0.82%	93.19B
SAMSUNG BIOLOGICS CO.,LTD.	-1.32%	39.62B
BIOGEN INC.	-12.88%	33.78B
UCB	+64.77%	26.82B
BIOMARIN PHARMACEUTICAL INC.	-16.31%	15.35B
INCYTE CORPORATION	-5.78%	13.13B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.38%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-49.84%	10.26B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	9.43B

Biopharmaceuticals

TRACON Pharmaceuticals, Inc.

Equities

TCON

US89237H3084

Pharmaceuticals

TRACON Pharmaceuticals Appoints Shahe Garabedian as Senior Vice President of Quality Assurance

Latest news about TRACON Pharmaceuticals, Inc.

Chart TRACON Pharmaceuticals, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Biopharmaceuticals